These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 14618776)

  • 1. An innovative method of collecting adverse events data.
    Kellogg VA
    Outcomes Manag; 2003; 7(4):174-80. PubMed ID: 14618776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events in acute care: an integrative literature review.
    Kellogg VA; Havens DS
    Res Nurs Health; 2003 Oct; 26(5):398-408. PubMed ID: 14579260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing indicators of inpatient adverse drug events through nonlinear analysis using administrative data.
    Nebeker JR; Yarnold PR; Soltysik RC; Sauer BC; Sims SA; Samore MH; Rupper RW; Swanson KM; Savitz LA; Shinogle J; Xu W
    Med Care; 2007 Oct; 45(10 Supl 2):S81-8. PubMed ID: 17909388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality assessment of anesthesia service at Siriraj Hospital.
    Chinachoti T; Suraseranivongse S; Valairucha S; Tritrakarn T
    J Med Assoc Thai; 2002 Sep; 85 Suppl 3():S866-74. PubMed ID: 12452223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an online morbidity, mortality, and near-miss reporting system to identify patterns of adverse events in surgical patients.
    Bilimoria KY; Kmiecik TE; DaRosa DA; Halverson A; Eskandari MK; Bell RH; Soper NJ; Wayne JD
    Arch Surg; 2009 Apr; 144(4):305-11; discussion 311. PubMed ID: 19380642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children's hospitals.
    Takata GS; Mason W; Taketomo C; Logsdon T; Sharek PJ
    Pediatrics; 2008 Apr; 121(4):e927-35. PubMed ID: 18381521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving self-reporting of adverse drug events in a West Virginia hospital.
    Schade CP; Hannah K; Ruddick P; Starling C; Brehm J
    Am J Med Qual; 2006; 21(5):335-41. PubMed ID: 16973950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An intervention to decrease narcotic-related adverse drug events in children's hospitals.
    Sharek PJ; McClead RE; Taketomo C; Luria JW; Takata GS; Walti B; Tanski M; Nelson C; Logsdon TR; Thurm C; Federico F
    Pediatrics; 2008 Oct; 122(4):e861-6. PubMed ID: 18829784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
    Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J
    Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic identification and classification of adverse events in human research.
    Silverman DI; Cirullo L; DeMartinis NA; Damato K; DeMeo M; Fernandez GA; Glynn L; Hegde U; Laskay E; Leger R; Abu-Hasaballah K; Caron JM
    Contemp Clin Trials; 2006 Jun; 27(3):295-303. PubMed ID: 16624631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pitfalls of adverse event reporting in paediatric cardiac intensive care.
    Ricci M; Goldman AP; de Leval MR; Cohen GA; Devaney F; Carthey J
    Arch Dis Child; 2004 Sep; 89(9):856-9. PubMed ID: 15321866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of adverse events associated with triptans--methods of assessment influence the results.
    Sheftell FD; Feleppa M; Tepper SJ; Rapoport AM; Ciannella L; Bigal ME
    Headache; 2004; 44(10):978-82. PubMed ID: 15546260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse event reporting: lessons learned from 4 years of Florida office data.
    Coldiron B; Fisher AH; Adelman E; Yelverton CB; Balkrishnan R; Feldman MA; Feldman SR
    Dermatol Surg; 2005 Sep; 31(9 Pt 1):1079-92; discussion 1093. PubMed ID: 16162309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Making the most of spontaneous adverse drug reaction reporting.
    Waller PC
    Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):320-3. PubMed ID: 16611209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005.
    Moore TJ; Cohen MR; Furberg CD
    Arch Intern Med; 2007 Sep; 167(16):1752-9. PubMed ID: 17846394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication safety program reduces adverse drug events in a community hospital.
    Cohen MM; Kimmel NL; Benage MK; Cox MJ; Sanders N; Spence D; Chen J
    Qual Saf Health Care; 2005 Jun; 14(3):169-74. PubMed ID: 15933311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug event reporting in intensive care units: a survey of current practices.
    Kane-Gill SL; Devlin JW
    Ann Pharmacother; 2006; 40(7-8):1267-73. PubMed ID: 16849619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in collecting, accessing and evaluating post market surveillance AERS in patients receiving dietary supplements.
    Kingston R
    Thromb Res; 2005; 117(1-2):137-44; discussion 145-51. PubMed ID: 16139875
    [No Abstract]   [Full Text] [Related]  

  • 20. Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials.
    Mahoney MR; Sargent DJ; O'Connell MJ; Goldberg RM; Schaefer P; Buckner JC
    J Clin Oncol; 2005 Dec; 23(36):9275-81. PubMed ID: 16361625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.